-+ 0.00%
-+ 0.00%
-+ 0.00%

Jaguar Health Announces Acceptance Of Two Late Breaking Abstracts To Treat Pediatric Intestinal Failure From Microvillus Inclusion Disease And Short Bowel Syndrome

Benzinga·04/24/2026 12:32:13
Listen to the news

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual Meeting of ESPGHAN. These pediatric IF patients are receiving liquid oral crofelemer as an investigational drug under two separate investigator-initiated trials. One infant MVID IF patient is being treated with crofelemer as adjunctive therapy to parenteral support for more than 6 months and other pediatric patients with IF due to MVID and/or SBS received crofelemer adjunctive therapy for over 1 year together with reduced amounts of parenteral support (PS).